Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus

Author: Chen, Songyuan

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 3, Number 2, June 2009 , pp. 135-143(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $104.88 plus tax (Refund Policy)

Abstract:

Diabetes mellitus occurs when pancreatic β-cell performance is compromised, due to either loss of the β-cell mass and/or decreased β-cell function. The regeneration of β-cells in vivo is providing a novel potential therapeutic approach to replace the β-cells lost by autoimmune destruction in type 1 diabetes; or restore the β-cell mass and β-cell function damaged by the failure of compensation in type 2 diabetes. The data obtained from the rodents indicate that adult β-cells replicate primarily from pre-existing β-cells, rather than from non-β-cell precursors. Furthermore, the β-cell replication is regulated sensitively by specific cellular factors. The positive results from the combination therapy of the gastrin-based, plus biological factors are attracting more attention. The evidences have implied that this might be an important step in curing diabetes, rather than just lowering the blood glucose level by the administration of oral hypoglycemic drugs or the exogenous insulin injection for the patients with diabetes. The present review summarizes the advances and recent patents in the field of β-cell replication in vivo and the regulation of β-cell renewal.

Keywords: Diabetes; islet; β-cells; proliferation; β-cell regeneration; β-cell apoptosis

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187221409788452372

Publication date: 2009-06-01

More about this publication?
  • Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page